Details

Last Funding Type

Post-IPO Debt

Last Funding Money Raised

$750M

Industries

Biotechnology,Genetics,Health Care,Medical

Founded date

Jan 1, 1998

Number Of Employee

5001 - 10000

Operating Status

Active

Investor Type

Accelerate

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.